# Structure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions

**Authors:** Ahmet Bugra Aksel, Fikriye Ozgencil, Filiz Bakar‐Ates, Habibe Beyza Gunindi, Alberto Massarotti, Erva Ozkan, Selen Gozde Kaya, Mahmut Gozelle, Yesim Ozkan, Gokcen Eren

PMC · DOI: 10.1002/ddr.70256 · 2026-03-10

## TL;DR

This paper describes the design and testing of new SIRT2 inhibitors that show improved activity and biological effects in cancer cells.

## Contribution

The study introduces optimized 1,3,4-thiadiazole-based SIRT2 inhibitors with validated antiproliferative effects and binding stability.

## Key findings

- ST132 showed an IC50 of 6.62 µM and increased acetylated α-tubulin in MCF-7 cells.
- Docking and MD simulations confirmed the stability and binding interactions of ST132 with SIRT2.
- The inhibitors' structural features at the binding site entrance were identified as key for activity.

## Abstract

SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC50 values in the micromolar range. To further optimize their activity, we performed molecular docking‐guided design and subsequent synthesis of a series of novel 1,3,4‐thiadiazole derivatives. SIRT inhibitory screening identified that ST131 and ST132 achieved moderate inhibitory effects against SIRT2 with IC50 values of 8.95 and 6.62 µM, respectively. Moreover, cellular assays in MCF‐7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α‐tubulin expression levels, which is typically consistent with SIRT2 inhibition. In addition, docking studies were performed to analyze and rationalize the structural differences responsible for SIRT2 activity, shedding light on the importance of the interactions occurring at the entrance of the binding site. Finally, molecular mechanics‐generalized born surface area (MM‐GBSA) and molecular dynamics (MD) simulation approaches were conducted to verify the stability of ST132 in the complex with SIRT2.

## Linked entities

- **Proteins:** SIRT2 (sirtuin 2), LOC126710533 (tubulin alpha chain-like)
- **Diseases:** cancer (MONDO:0004992), obesity (MONDO:0011122), bacterial infection (MONDO:0005113)

## Full-text entities

- **Genes:** PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SIRT6 (sirtuin 6) [NCBI Gene 51548] {aka SIR2L6, hSIRT6}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SIRT2 (sirtuin 2) [NCBI Gene 22933] {aka SIR2, SIR2L, SIR2L2}, SIRT7 (sirtuin 7) [NCBI Gene 51547] {aka SIR2L7}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, CAPN3 (calpain 3) [NCBI Gene 825] {aka CANP3, CANPL3, LGMD2, LGMD2A, LGMDD4, LGMDR1}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}
- **Diseases:** cardiac injury (MESH:D006331), obesity (MESH:D009765), breast cancer (MESH:D001943), bacterial infection (MESH:D001424), metabolic disorders (MESH:D008659), viral (MESH:D014777), fibrosis (MESH:D005355), neurodegeneration (MESH:D019636), inflammation (MESH:D007249), cytotoxic (MESH:D064420), cancer (MESH:D009369)
- **Chemicals:** thiophene (MESH:D013876), E325 (MESH:D019354), alumina (MESH:D000537), Fe (MESH:D007501), CO2 (MESH:D002245), N-methylaniline (MESH:C021313), amide (MESH:D000577), H2O (MESH:D014867), thiadiazole (MESH:D013830), 13C (MESH:C000615229), NaOH (MESH:D012972), EDC (MESH:C024565), ethanol (MESH:D000431), acetamide (MESH:C030686), DMSO (MESH:D004121), brine (MESH:C017082), SDS (MESH:D012967), acetic acid (MESH:D019342), 1,3-benzodioxole (MESH:C040539), H (MESH:D006859), HCl (MESH:D006851), sodium acetate (MESH:D019346), PBS (MESH:D007854), suramin (MESH:D013498), NAD+ (MESH:D009243), Tween (MESH:D011136), 1,3,4-Thiadiazole (MESH:C058949), 2-amino-1,3,4-thiadiazoles (MESH:C010852), zinc (MESH:D015032), oxygen (MESH:D010100), Na+ (MESH:D012964), EX-527 (MESH:C550547), formazan (MESH:D005562), POCl3 (MESH:C013196), silica (MESH:D012822), n-hexane (MESH:C026385), salt (MESH:D012492), methanol (MESH:D000432), sulfur (MESH:D013455), 3H (MESH:D014316), ST135 (MESH:C000603149), Acetic anhydride (MESH:C031800), 5-[(4-nitrophenoxy)methyl]-1,3,4-thiadiazol-2-amine (-), 2H (MESH:D003903), NaHCO3 (MESH:D017693), ethyl acetate (MESH:C007650), silica gel (MESH:D058428), acetone (MESH:D000096), triethylamine (MESH:C016162), MP (MESH:C063925), ester (MESH:D004952), acetonitrile (MESH:C032159), Cl- (MESH:D002713), amine (MESH:D000588), TMS (MESH:C073196), NH4Cl (MESH:D000643), isoxazole (MESH:D007555), MTT (MESH:C070243), dichloromethane (MESH:D008752), thiosemicarbazide (MESH:C005151)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12973487/full.md

---
Source: https://tomesphere.com/paper/PMC12973487